Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Nephrology · Membranous Nephropathy

Building Your Care Team: Specialists and Screenings

At a Glance

Membranous nephropathy often needs a nephrologist experienced in glomerular disease and evaluation for cancer, lupus, medicines, supplements, or exposures that could be contributing. Before treatment that lowers immune activity, review vaccines and infection tests with your care team.

Managing membranous nephropathy (MN) is complex and often requires a team of experts working together. Because MN is a rare “glomerular” disease—one that affects the kidney’s filters—the most important member of your team is a nephrologist who specializes in glomerulonephritis (GN) [1]. While many nephrologists focus on dialysis, you need a specialist who is experienced in the nuances of autoimmune kidney disease and immune-suppressing medications.

The “Search for a Cause” (Secondary Evaluation)

Before solidifying a treatment plan, your care team must perform a “secondary evaluation.” This is a detailed hunt to see if your MN is being triggered by another condition [2]. If an underlying cause is found, your kidney disease may be treated by tailoring care to the root cause, though immune therapy might still be needed [3].

1. Cancer Screening (Oncology)

In some cases, MN is associated with an underlying cancer. This association is sometimes seen if your biopsy shows the THSD7A or NELL-1 antigens [4][5].

  • Who is involved: Your nephrologist or primary doctor, and sometimes an oncologist.
  • The Process: You should be up to date on all routine age-appropriate screenings, such as colonoscopies, mammograms, or prostate screening [6]. If you are at higher risk (e.g., a history of smoking or unexplained weight loss), your doctor may order more targeted imaging, like a CT scan of the chest or abdomen [7][8]. Note that a positive antigen is not a cancer diagnosis.

2. Autoimmune Evaluation (Rheumatology)

If your biopsy shows the EXT1 or EXT2 antigens, there is a likelihood that your MN is related to Systemic Lupus Erythematosus (Lupus) or another autoimmune condition [9].

  • Who is involved: A rheumatologist.
  • The Process: They will run specialized blood tests, such as ANA (Antinuclear Antibody), anti-dsDNA, and complement levels (C3/C4) [10][11]. Even if these tests are negative today, your team will continue to monitor you, as lupus can sometimes appear years after the kidney symptoms first begin [12][13].

3. Environmental and Medication Review

Your team will review your medications and supplements.

  • Mercury Exposure: Certain imported skin-lightening creams or traditional medicines can contain mercury, which is a known trigger for NELL-1 associated MN [14][15].
  • Supplements: Alpha-lipoic acid (ALA) has been linked in some reports to NELL-1 positive MN. In some cases, stopping the supplement is recommended, though it does not guarantee remission [16][17].
  • NSAIDs: Regular use of pain relievers like ibuprofen or naproxen can also occasionally be associated with MN and should be reviewed [3].

Essential Steps Before Treatment

If your team decides that you need immunosuppression (like rituximab or cyclophosphamide), there is an important prep phase.

The Vaccination Window
Drugs like rituximab work by depleting your B-cells. Once these cells are gone, your body’s response to new vaccines may be reduced [18].

  • Action Step: Your care team will want you to receive necessary vaccinations (such as the flu shot or pneumonia vaccine) before starting treatment [19]. Timing differs for live versus non-live vaccines, and urgent kidney treatment should not automatically be delayed.
  • Infection Screening: Your team will also test you for infections like Hepatitis B, Hepatitis C, or Tuberculosis. If Hepatitis B is positive, a specific antiviral prophylaxis plan is required [20][2].

Common questions in this guide

Which doctor should coordinate care for membranous nephropathy?
A nephrologist with experience in glomerular diseases and autoimmune kidney disease is usually the central specialist. The nephrologist may coordinate with a primary care clinician, oncologist, or rheumatologist depending on the suspected cause and treatment plan.
Why am I being checked for another cause of membranous nephropathy?
Membranous nephropathy can sometimes be linked to cancer, lupus or another autoimmune illness, medicines, supplements, or environmental exposures. Finding an underlying cause can change how the kidney disease is treated, although immune-lowering treatment may still be needed.
Does a positive THSD7A or NELL-1 result mean I have cancer?
No. These biopsy findings can be associated with an underlying cancer in some people, so your clinician may recommend routine age-appropriate screening and, when appropriate, more targeted tests. A positive antigen result by itself is not a cancer diagnosis.
What tests can look for lupus linked to membranous nephropathy?
A rheumatologist may order blood tests such as ANA, anti-dsDNA, and complement levels called C3 and C4. Negative results do not necessarily rule out lupus developing later, so continued follow-up may be recommended.
Could a medicine or supplement be contributing to my MN?
Your care team should review prescription and over-the-counter medicines, supplements, and exposures, including mercury-containing imported skin-lightening products or traditional medicines, alpha-lipoic acid, and regular NSAID use such as ibuprofen or naproxen. Do not stop a prescribed medicine or supplement without discussing it with your clinician, because stopping a suspected trigger does not always lead to remission.
What needs to happen before starting rituximab or cyclophosphamide?
Your team may update needed vaccines, such as influenza or pneumonia vaccination, before treatment because rituximab can reduce the response to new vaccines; timing depends on the vaccine and treatment urgency. Screening for hepatitis B, hepatitis C, and tuberculosis is also important, and a positive hepatitis B test may require antiviral prevention during treatment.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on membranous glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does your practice specialize in glomerular diseases (GN), and how many patients with membranous nephropathy do you currently manage?
  2. 2.Since my [Antigen Name] was positive, what specific cancer screening tests do I need beyond a standard physical?
  3. 3.Can we review all my supplements, including any alpha-lipoic acid or traditional medicines, to see if they could be triggering my MN?
  4. 4.Which vaccines do I need to complete before we start my first dose of rituximab?
  5. 5.Who will be my point of contact if I develop a fever or signs of an infection while on immunosuppression?

References

References (20)
  1. 1

    Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.

    Rovin BH, Almaani S, Malvar A

    Kidney international 2019; (95(2)):265-267 doi:10.1016/j.kint.2018.11.016.

    PMID: 30665567
  2. 2

    Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms.

    Murtas C, Ghiggeri GM

    Journal of nephrology 2016; (29(4)):469-78 doi:10.1007/s40620-016-0268-7.

    PMID: 26810113
  3. 3

    Drug-Induced Membranous Nephropathy: Piecing Together Clues to Understand Disease Mechanisms.

    Avasare RS, Andeen NK, Al-Rabadi LF, et al.

    Journal of the American Society of Nephrology : JASN 2025; (36(8)):1629-1638 doi:10.1681/ASN.0000000719.

    PMID: 40198910
  4. 4

    An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy.

    Hoxha E, Beck LH, Wiech T, et al.

    Journal of the American Society of Nephrology : JASN 2017; (28(2)):520-531 doi:10.1681/ASN.2016010050.

    PMID: 27436855
  5. 5

    A Clinicopathologic Study of Neural Epidermal Growth Factor-Like 1-Associated Membranous Nephropathy in a Chinese Cohort.

    Xu J, Hu X, Zhu Y, et al.

    Kidney international reports 2026; (11(8)):106613 doi:10.1016/j.ekir.2026.106613.

    PMID: 42318536
  6. 6

    Malignancies and glomerulonephritis: when to suspect and when to screen?

    Murt A, Berke I, Bruchfeld A, et al.

    Clinical kidney journal 2025; (18(5)):sfaf101 doi:10.1093/ckj/sfaf101.

    PMID: 40352576
  7. 7

    Malignancy-associated membranous nephropathy: focus on diagnosis and treatment.

    Ai S, Yan X, Zhao X, et al.

    Journal of nephrology 2023; (36(8)):2355-2363 doi:10.1007/s40620-023-01751-4.

    PMID: 37713160
  8. 8

    Paraneoplastic Glomerular Diseases.

    Jeyabalan A, Trivedi M

    Advances in chronic kidney disease 2022; (29(2)):116-126.e1 doi:10.1053/j.ackd.2022.02.009.

    PMID: 35817519
  9. 9

    Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.

    Sethi S, Madden BJ, Debiec H, et al.

    Journal of the American Society of Nephrology : JASN 2019; (30(6)):1123-1136 doi:10.1681/ASN.2018080852.

    PMID: 31061139
  10. 10

    Sjögren's syndrome complicated with membranous nephropathy, a cause or coincidence?

    Chen R, Wang J, Xie Q, et al.

    International journal of rheumatic diseases 2021; (24(8)):1086-1094 doi:10.1111/1756-185X.14168.

    PMID: 34223708
  11. 11

    Detection of Exostosin 1 in Lupus Nephritis: Prevalence, Clinico-Pathologic and Renal Outcome Correlations.

    Assis LL, Malheiros DMAC, Zanetta DM, Yu L

    Diagnostics (Basel, Switzerland) 2026; (16(11)) doi:10.3390/diagnostics16111591.

    PMID: 42279461
  12. 12

    A case of membranous nephropathy diagnosed with lupus nephritis 11 years after onset.

    Yamada T, Itagaki F, Aratani S, et al.

    CEN case reports 2019; (8(4)):301-307 doi:10.1007/s13730-019-00412-5.

    PMID: 31399881
  13. 13

    Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population.

    Miller P, Lei L, Charu V, et al.

    Pediatric nephrology (Berlin, Germany) 2022; (37(12)):3127-3137 doi:10.1007/s00467-022-05503-7.

    PMID: 35333973
  14. 14

    Complementary and alternative medicine-associated membranous nephropathy: a systematic review.

    Nguyen MK, Chou A, Ramachandran R, et al.

    Journal of nephrology 2026; (39(2)):259-266 doi:10.1093/joneph/aajaf036.

    PMID: 42148864
  15. 15

    NELL-1 membranous nephropathy due to mercury exposure from fairness cream: Report of two cases.

    Jawandhiya P, Gupta A

    Nephrology (Carlton, Vic.) 2024; (29(12)):996-999 doi:10.1111/nep.14403.

    PMID: 39397329
  16. 16

    Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers.

    Avasare RS, Clark S, Spain RI, et al.

    Kidney international reports 2024; (9(5)):1379-1386 doi:10.1016/j.ekir.2024.02.1401.

    PMID: 38707817
  17. 17

    Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.

    Spain RI, Andeen NK, Gibson PC, et al.

    Kidney international 2021; (100(6)):1208-1213 doi:10.1016/j.kint.2021.10.010.

    PMID: 34662650
  18. 18

    Ten tips on immunosuppression in primary membranous nephropathy.

    Trujillo H, Caravaca-Fontán F, Praga M

    Clinical kidney journal 2024; (17(6)):sfae129 doi:10.1093/ckj/sfae129.

    PMID: 38915435
  19. 19

    Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study.

    Sans-Pola C, Agustí A, Bosch JÀ, et al.

    Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10214941.

    PMID: 34768461
  20. 20

    Membranous nephropathy.

    Ronco P, Beck L, Debiec H, et al.

    Nature reviews. Disease primers 2021; (7(1)):69 doi:10.1038/s41572-021-00303-z.

    PMID: 34593809

This page is for informational purposes only and does not constitute medical advice. Your nephrologist and other clinicians should tailor cancer screening, autoimmune testing, vaccinations, and treatment planning to your situation.